Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 10,000 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $104.97, for a total transaction of $1,049,700.00. Following the transaction, the senior vice president directly owned 14,219 shares of the company’s stock, valued at approximately $1,492,568.43. This represents a 41.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, October 12th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.60, for a total transaction of $805,919.40.
• On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.75, for a total transaction of $51,034.75.
• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.

Oruka Therapeutics Stock Up 0.3%

Shares of NASDAQ:ORKA traded up $0.36 during trading hours on Friday, hitting $105.35. 679,678 shares of the company’s stock traded hands, compared to its average volume of 1,033,539. Oruka Therapeutics, Inc. has a 1 year low of $25.23 and a 1 year high of $115.51. The business has a fifty day moving average price of $89.68 and a 200-day moving average price of $72.36.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). On average, equities analysts predict that Oruka Therapeutics, Inc. will post -2.52 EPS for the current year.

Top Oruka Therapeutics Stories

These are some of the ORKA stories that stood out recently:

• Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
• Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
• Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in ORKA. First Trust Advisors LP grew its position in Oruka Therapeutics by 1,248.6% in the 3rd quarter. First Trust Advisors LP now owns 62,885 shares of the company’s stock valued at $5,238,000 after acquiring an additional 58,222 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of Oruka Therapeutics by 2.9% in the 3rd quarter. Voya Investment Management LLC now owns 412,814 shares of the company’s stock valued at $34,383,000 after purchasing an additional 11,665 shares in the last quarter. Public Sector Pension Investment Board acquired a new stake in Oruka Therapeutics in the third quarter valued at $2,841,000. Virtus Advisers LLC lifted its stake in Oruka Therapeutics by 25.0% during the third quarter. Virtus Advisers LLC now owns 5,908 shares of the company’s stock worth $492,000 after purchasing an additional 1,182 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Oruka Therapeutics by 217.6% in the 3rd quarter. Fisher Asset Management LLC now owns 215,593 shares of the company’s stock valued at $17,957,000 after buying an additional 147,719 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ORKA has been the subject of several recent analyst reports. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Guggenheim reiterated a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a report on Monday, October 26th. Wedbush reiterated an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $141.80.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.